All News

Global Orphan Drug Market Research Report 2020-2026||Competitive Analysis By AbbVie, AstraZeneca, Baxter, Eli Lilly and Company, Johnson & Johnson Services Inc., Merck KGaA

Global orphan drug market is rise gradually to an estimated value of USD 326.25 billion by 2026 registering a CAGR of 8.5% in the forecast period of 2019-2026. Growing number of orphan diseases, accelerating novel therapies and orphan drug development programs and exclusive incentives from the government are the key factors for market growth.

The Orphan Drug market Report deliver comprehensive analysis of the market structure along with forecast of the various segments and sub-segments of the market. This report is a through synopsis of the Study done on Orphan Drug market’s key vendor revenues, development of the industry by upstream & downstream, industry progress, key companies, along with type segment & market applications. Analysis and discussion of important industry trends, market size, market share estimates are mentioned in the report. The Orphan Drug market report is generated based on the market type, size of the organization, availability on-premises and the end-users’ organization type, and the availability in areas such as North America, South America, Europe, Asia-Pacific and Middle East & Africa.

Get Sample Copy Of This Report+ All Related Graphs @

Few of the major competitors currently working in the global  orphan  disease market are F. Hoffmann-La Roche Ltd.,  Novartis AG, Pfizer Inc., AbbVie, AstraZeneca, Baxter, Eli Lilly and Company, Johnson & Johnson Services Inc., Merck KGaA, Novo Nordisk A/S, Bristol-Myers Squibb Company, Alexion Pharmaceuticals, Kyowa Hakko Kirin Co., Ltd., Amgen Inc., Biogen, Celldex Therapeutics, GlaxoSmithKline plc., Eisai Co., Ltd., Takeda Pharmaceutical Company Limited, Vertex Pharmaceuticals Incorporated (US)  and among others.

Key Developments in the Market:

In August 2018, Kyowa Hakko Kirin Co., Ltd received the FDA approval for Poteligeo (mogamulizumab-kpkc) injection, an Orphan Drug, for the treatment of adult patients with relapsed or refractory mycosis fungoides or Sezary syndrome which are the types of non-Hodgkin lymphoma

In August 2018, Takeda Pharmaceutical Company Limited received FDA approval for Takhzyro (lanadelumab-flyo) injection for the treatment to hereditary angioedema (HAE) attack in patients 12 years of age and older

In June, 2018, Ascendis Pharma A/S received the FDA Orphan Drug Designation for TransCon PTH for the treatment of hypoparathyroidism. TransCon PTH is a long acting parathyroid hormone replacement therapy which helps in restoring the activity of parathyroid hormone

Segmentation: Global Orphan Drug Market

By Disease Type

(Oncology disease, Metabolic Disease, Hepatology, Immunology, Infection, Neurology and Others),

Drug Type

(Biological, Non-Biological, and Others),

Indication Type

(Non-Hodgkin Lymphoma, Acute Myeloid Leukemia, Cystic Fibrosis, Glioma, Pancreatic Cancer, Ovarian Cancer, Multiple Myeloma, Duchenne Muscular Dystrophy, Renal Cell Carcinoma and Others),

Drug class

(Lenalidomide, Rituximab, Glatiramer Acetate, Nivolumab, Interferon Beta-1a, Ibrutinib, Cinacalcet Hydrochloride, Imatinib Mesylate, Bortezomib, Sodium Oxybate and Others),

Therapy Type

(Medication, Surgery and Others),

Route of Administration

(Oral, Intravenous and Others),

End- users

(Hospitals, Homecare, Specialty Clinics, Others),


(North America, South America, Europe, Asia-Pacific, Middle East and Africa)

Enquire Here Get customization & check discount for report @:

Purview of the report

  1. To gain information about the top players in this industry, their product portfolios, and their key strategies.
  2. To describe major factors (drivers, restraints, opportunities, and challenges) influencing the growth of the Orphan Drug market and submarkets.
  3. To gain information about the top players in this industry, their product portfolios, and their key strategies.
  4. Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
  5. The report offers market share appraisals for regional and global levels

Table of Contents:

1 Introduction

2 Research Methodologies

3 Executive Summary

4 Premium Insights

5 Market Overview

6 Industry Trends

7 Compliance in Orphan Drug Market

8 Orphan Drug Market, By Service

9 Orphan Drug Market, By Deployment Type

10 Orphan Drug Market, By Organization Size

11 Orphan Drug Market Analyses, By Vertical

12 Geographic Analyses

  • North America
  • Europe
  • Asia-Pacific
  • South America
  • Middle East & Africa

13 Competitive Landscapes

14 Detailed Company Profiles

15 Related Reports

To know more about the study @

About Data Bridge Market Research

An absolute way to forecast what future holds is to comprehend the trend today!

Data Bridge set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process.

Data bridge is an aftermath of sheer wisdom and experience which was formulated and framed in the year 2015 in Pune. We ponder into the heterogeneous markets in accord with our clients needs and scoop out the best possible solutions and detailed information about the market trends. Data Bridge delve into the markets across Asia, North America, South America, Africa to name few.

Data Bridge adepts in creating satisfied clients who reckon upon our services and rely on our hard work with certitude. We are content with our glorious 99.9 % client satisfying rate.

Data Bridge Market Research
Tel: +1-888-387-2818
Email: [email protected]